Why can't children use plecanatide?

It carries a boxed warning and is contraindicated under age 6 due to a risk of serious dehydration, and it should be avoided from ages 6 to under 18.

What is the most common side effect?

Diarrhea is the most common side effect and can be severe; the drug should be stopped if severe diarrhea occurs.

Is plecanatide a supplement or a research peptide?

No. It is a prescription GI peptide medicine (Trulance) used under a doctor's care, not a supplement or research chemical.

EMA-approvedaka Trulance

Plecanatide — Complete Research Guide (2026)

Q: How does plecanatide work?

It activates guanylate cyclase-C in the gut, increasing fluid secretion into the intestine, which softens stool and speeds transit.

Last updated 2026-06-30

TL;DR

Plecanatide (also known as Trulance) is a peptide catalogued under Gastrointestinal (Guanylate cyclase-C agonist). It is described as: GC-C receptor. Documented context: Chronic idiopathic constipation; IBS-C. Neutral reference entry; EU status: EU-approved prescription medicine.

What is Plecanatide?

Plecanatide (brand name Trulance) is an orally administered guanylate cyclase-C (GC-C) agonist peptide, a uroguanylin analog, approved by the U.S. FDA for chronic idiopathic constipation (CIC) and for irritable bowel syndrome with constipation (IBS-C) in adults.

Its approval is supported by pivotal phase 3 randomized, double-blind, placebo-controlled trials.

It is a prescription gastrointestinal medicine, not a research or performance peptide.

How does Plecanatide work?

Plecanatide activates guanylate cyclase-C on the luminal surface of intestinal epithelial cells, raising intracellular cyclic GMP.

This increases secretion of chloride and bicarbonate into the intestinal lumen, drawing in fluid, softening stool, and accelerating transit.

What does the research say about Plecanatide?

In chronic idiopathic constipation, plecanatide increases the frequency of complete spontaneous bowel movements versus placebo. ^[1]
In IBS-C, plecanatide relieves abdominal and bowel symptoms significantly more than placebo across two phase 3 trials. ^[2]
Pooled phase 3 data confirm consistent, durable improvement of IBS-C symptoms with plecanatide. ^[3]

Clinical research & studies

The references below are the primary sources cited throughout this guide. Each links directly to PubMed or the regulator. Where evidence is preclinical (animal or in-vitro), that is stated rather than implied.

[1] A Randomized Phase III Clinical Trial of Plecanatide, a Uroguanylin Analog, in Patients With Chronic Idiopathic Constipation — Miner PB Jr et al., American Journal of Gastroenterology 2017. (Phase 3 randomized controlled trial)
[2] Efficacy, safety, and tolerability of plecanatide in patients with irritable bowel syndrome with constipation: results of two phase 3 randomized clinical trials — Brenner DM et al., American Journal of Gastroenterology 2018. (Two phase 3 randomized controlled trials)
[3] Plecanatide Improves Symptoms of Irritable Bowel Syndrome with Constipation: Results of an Integrated Efficacy and Safety Analysis of Two Phase 3 Trials — Brenner DM et al., International Journal of General Medicine 2023. (Integrated (pooled) analysis of phase 3 trials)
[4] Benefit-Risk Assessment of Plecanatide in the Treatment of Chronic Idiopathic Constipation — Miner PB Jr et al., Drug Safety 2019. (Benefit-risk review)
[5] Efficacy and safety of plecanatide in treating constipation predominant irritable bowel syndrome — Miner PB Jr et al., Expert Opinion on Pharmacotherapy 2018. (Review)

Dosing context

This is not medical advice or a usage recommendation. Dosing figures are reported research context only, cited from the published literature.

For context only and not as guidance: plecanatide is prescribed as a 3 mg tablet taken orally once daily for adults with CIC or IBS-C, with or without food.

Dosing decisions, eligibility, and monitoring are handled by a prescribing clinician.

Side effects & safety profile

Plecanatide carries an FDA boxed warning and is contraindicated in pediatric patients under 6 years of age because of the risk of serious, potentially fatal dehydration seen with GC-C agonists in juvenile animals, a class effect it shares with linaclotide; use should also be avoided in patients aged 6 to less than 18 years.

It is contraindicated in patients with known or suspected mechanical gastrointestinal obstruction.

The most common adverse effect is diarrhea, which can be severe and warrants stopping the drug; it is a prescription medicine and should be used only under medical supervision.

Stacking & combinations

Plecanatide is a prescription bowel medicine rather than a stackable supplement, and combining it with other laxatives or GC-C agonists is unnecessary and a clinician-only decision.

Finding Plecanatide vendors

This is an independent, neutral directory — we sell nothing and route no purchases. Use it to read regulatory context and (where available) genuine, moderated vendor information for your country.

Choose your country

We never list placeholder vendors. Pick your country to see neutral regulatory context.

Browse the directory

User reviews

No reviews yet

Reviews appear here once submitted and moderated. An aggregate rating is shown only after at least 5 genuine reviews — we never fabricate ratings.

Frequently asked questions

It is FDA-approved in adults for chronic idiopathic constipation and for irritable bowel syndrome with constipation (IBS-C).

References

[1] A Randomized Phase III Clinical Trial of Plecanatide, a Uroguanylin Analog, in Patients With Chronic Idiopathic Constipation — Miner PB Jr et al., American Journal of Gastroenterology 2017. PMID: 28169285. View sourceStudy: Phase 3 randomized controlled trialPlecanatide 3 mg significantly increased complete spontaneous bowel movements in CIC versus placebo.
[2] Efficacy, safety, and tolerability of plecanatide in patients with irritable bowel syndrome with constipation: results of two phase 3 randomized clinical trials — Brenner DM et al., American Journal of Gastroenterology 2018. PMID: 29545635. View sourceStudy: Two phase 3 randomized controlled trialsPlecanatide met the FDA composite responder endpoint for IBS-C, with diarrhea the main adverse event.
[3] Plecanatide Improves Symptoms of Irritable Bowel Syndrome with Constipation: Results of an Integrated Efficacy and Safety Analysis of Two Phase 3 Trials — Brenner DM et al., International Journal of General Medicine 2023. PMID: 37649852. View sourceStudy: Integrated (pooled) analysis of phase 3 trialsPooled analysis confirmed consistent IBS-C symptom improvement and a favorable tolerability profile.
[4] Benefit-Risk Assessment of Plecanatide in the Treatment of Chronic Idiopathic Constipation — Miner PB Jr et al., Drug Safety 2019. PMID: 30649746. View sourceStudy: Benefit-risk reviewAssesses plecanatide's efficacy against its safety profile, notably diarrhea and pediatric contraindication.
[5] Efficacy and safety of plecanatide in treating constipation predominant irritable bowel syndrome — Miner PB Jr et al., Expert Opinion on Pharmacotherapy 2018. PMID: 29376436. View sourceStudy: ReviewSummarizes plecanatide's mechanism, IBS-C efficacy, and tolerability including diarrhea.

This article is for educational and research purposes only. Peptides discussed here are not approved for human consumption by the FDA, EMA, or equivalent regulators outside of specific clinical contexts. Always consult a licensed medical professional before any therapeutic use.